Prior Immune Checkpoint Inhibitor Treatment Is a Risk Factor for Treatment‐Related Adverse Events in Unresectable Hepatocellular Carcinoma Treated With Durvalumab Plus Tremelimumab

Ähnliche Einträge

• Effect of Butyrate‐Producing Enterobacteria and Proton Pump Inhibitors on Advanced Hepatocellular Carcinoma Treatment With Durvalumab and Tremelimumab
  von: Kazuhiro Nouso, et al.
  Veröffentlicht: (2026)
• Higher Absolute Lymphocyte Counts and Lower Des‐γ‐Carboxyprothrombin Levels After Treatment Initiation Are Associated With the Clinical Efficacy of Tremelimumab Plus Durvalumab Combination Therapy for Hepatocellular Carcinoma
  von: Yuta Inoue, et al.
  Veröffentlicht: (2025)
• Endoscopic Innovation Treatment Strategy in Hepatocellular Carcinoma ( HCC ) Patients Before Immunotherapy: A Case Series Study in Unselected Patients
  von: Stephen Dario Syofyan, et al.
  Veröffentlicht: (2026)
• Prediction of Hepatocellular Carcinoma After Direct‐Acting Antiviral Therapy Using Agile 3+ and End‐of‐Treatment Alpha‐Fetoprotein Levels in Patients With Hepatitis C
  von: Akifumi Kuwano, et al.
  Veröffentlicht: (2025)
• Challenges in the Treatment of Hepatorenal Syndrome–Acute Kidney Injury: A US Chart Review of Treatment Patterns and Survival Outcomes
  von: Arun J. Sanyal, et al.
  Veröffentlicht: (2025)